|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG005326915 |
| 003 |
DE-627 |
| 005 |
20230425183300.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2018 xx |||||o 00| ||dan c |
| 035 |
|
|
|a (DE-627)CTG005326915
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)IRCT20180510039601N1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a dan
|
| 245 |
1 |
0 |
|a selenium in Hashimoto
|b The effects of selenium supplementation on Thyroid gland size in Hashimoto's thyroiditis
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2018-06-02, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Condition 1: Autoimmune thyroiditis,. Condition 2: Nontoxic goiter, unspecified. Autoimmune thyroiditis Nontoxic goiter, unspecified
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2/Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Completed
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2018) vom: 16. Juli
|
| 773 |
1 |
8 |
|g year:2018
|g day:16
|g month:07
|
| 856 |
4 |
0 |
|u http://en.irct.ir/trial/31101
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2018
|b 16
|c 07
|
Klinische Studie